2646
J. M. Gerdes et al. / Bioorg. Med. Chem. Lett. 10 (2000) 2643±2646
9. Chang, A.S.-S.; Chang, S. M.; Starnes, D. M. Eur. J.
Pharmacol. 1993, 247, 239.
24. Mathis, C. A.; Enas, J. D.; Hanrahan, S. M.; Akgun, E. J.
Labelled Compd. Radiopharm. 1994, 34, 905.
10. Clie, I.; Pike, V. W. Med. Chem. Res. 1995, 5, 77.
11. Dannals, R. F.; Scheel, U.; Suehiro, M.; Ricaurte, G.
Med. Chem. Res. 1995, 5, 228.
25. Applegate, H. E.; Cimarusti, C. M.; Dol®ni, J. E.; Funke,
P. T.; Koster, W. H.; Puar, M. S.; Slusarchyk, W. A.; Young,
M. G. J. Org. Chem. 1979, 44, 811.
12. Fowler, J. S.; Volkow, N. D.; Wang, G.-J.; Ding, Y.-S.;
Dewey, S. L. J. Nuc. Med. 1999, 180, 1154.
26. Hino, K.; Furukawa, K.; Nagail, Y.; Uno, H. Chem.
Pharm. Bull. 1980, 28, 2618.
13. Hashimoto, K.; Goromaru, T. Eur. J. Pharmacol. 1990,
180, 273.
14. Hashimoto, K.; Goromaru, T. Neuropharmacology 1991,
33, 113.
27. Zervas, L.; Theodoropoulos, D. M. J. Am. Chem. Soc.
1956, 78, 1359.
28. Ligand 3 was isolated in pure form as an orange colored
1
glass; H NMR (400 MHz, CDCl3) d 1.35 (3H, d, J=7.1 Hz),
15. Hashimoto, K.; Goromaru, T. Neuropharmacology 1992,
31, 869.
16. Mathis, C. A.; Taylor, S. E.; Enas, J. D.; Akgun, E. J.
Pharm. Pharmacol. 1994, 46, 751.
17. Vaatstra, W. J.; Deiman-Van Aalst, W. M.; Eigeman, L.
Eur. J. Phamacol. 1981, 70, 195.
2.84 (1H, dt, J=12.3 Hz, 4.8 Hz), 2.98 (1H, d, J=11.5 Hz),
3.07 (1H, dd, J=12.5 Hz, 4.5 Hz), 3.14±3.28 (2H, m), 4.0±4.15
(1H, m), 4.46 (1H, br d, J=12.5 Hz), 4.68 (3H, br s), 7.03 (1H,
d, J=9.5 Hz), 7.64 (1H, d, J=9.1 Hz), 7.95 (1H, d, J=9.1 Hz),
8.29 (1H, dd, J=9.5 Hz, 2.5 Hz), 8.54 (1H, d, J=2.5 Hz).
Anal. (C14H16N4O2) C, H.
18. Concurrent with our studies, a recent report of the syn-
thesis of ligand 4 and assessment of its SERT anity
([3H]citalopram) has been aorded, Lee, B. S.; Chu, S.; Lee, B.
C.; Chi, D. Y.; Choe, Y. S.; Jeong, K. J.; Jin, C. Bioorg. Med.
Chem. Lett. 2000, 10, 1559.
19. Mathis, C. A.; Gerdes, J. M.; Enas, J. D.; Whitney, J. M.;
Taylor, S. E.; Zhang, Y.; McKenna, S.; Havlik, S.; Peroutka,
S. J. Pharm. Pharmacol. 1992, 44, 801.
29. Agent 4 was obtained in pure form as an orange-yellow
semi-solid; 1H NMR (400 MHz, CDCl3) d 1.20 (3H, d,
J=6.2 Hz), 1.75 (1H, br s), 2.70 (1H, t J=12.5 Hz), 2.6±3.00
(2H, m), 3.09 (1H, t, J=12.2 Hz), 3.18 (1H, d, J=12.1 Hz),
4.52 (2H, d, J=12.5 Hz), 7.07 (1H, d, J=9.0 Hz), 7.66 (1H, d,
J=9.5 Hz), 7.96 (1H, d, J=9.5 Hz), 8.30 (1H, dd, J=9.0 Hz,
2.5 Hz), 8.53 (1H, d, J=2.5 Hz). Anal. (C14H16N4O2) C, H.
30. Mathis, C. A.; Taylor, S. E.; Beigon, A.; Enas, J. Brain
Res. 1993, 619, 229.
31. Habert, E.; Graham, D.; Tahraoui, L.; Claustre, Y.; Lan-
ger, S. Z. Eur. J. Pharmacol. 1985, 118, 107.
32. Cheng, Y. C.; Pruso, W. H. Biochem. Pharmacol. 1973,
22, 3099.
20. Yields reported are of isolated puri®ed products and are
not optimized.
21. All synthetic intermediates and ®nal products were puri®ed
by column chromatography (silica gel 60, isopropylamine:ethyl
acetate/hexane, 1:1.5:7.5) with the exception of amine 6 which
was recrystallized from ether/hexane, 1:9 (mp 137±139 ꢀC).
22. Synthetic intermediates and ®nal products provided ana-
lytical data consistent with the assigned structures.
23. Rodriguez R. US Patent 3,737,540, 1973; Chem. Abstr.
1973, 79, 42,554.
33. During the time the binding assessments were performed,
ligand 2 was unavailable and, thus, the established EPMR
method of evaluation (ref 16) was used to compare ligand
potency (2 vs 3) from experiments performed at dierent times
and in separate laboratories.